Curis, Inc. (NASDAQ:CRIS) – Stock analysts at B. Riley reduced their Q2 2021 earnings per share estimates for Curis in a report issued on Thursday, May 13th. B. Riley analyst J. Walsh now expects that the biotechnology company will earn ($0.11) per share for the quarter, down from their previous estimate of ($0.09). B. Riley has a “Buy” rating and a $22.00 price objective on the stock. B. Riley also issued estimates for Curis’ Q3 2021 earnings at ($0.11) EPS, Q4 2021 earnings at ($0.11) EPS, FY2021 earnings at ($0.43) EPS, Q1 2022 earnings at ($0.12) EPS, Q2 2022 earnings at ($0.12) EPS, Q3 2022 earnings at ($0.13) EPS, Q4 2022 earnings at ($0.13) EPS, FY2022 earnings at ($0.50) EPS, FY2023 earnings at ($0.62) EPS, FY2024 earnings at ($0.76) EPS and FY2025 earnings at ($0.89) EPS.
Curis (NASDAQ:CRIS) last issued its earnings results on Wednesday, May 12th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The business had revenue of $2.19 million for the quarter, compared to the consensus estimate of $2.68 million.
Curis stock opened at $15.05 on Monday. The company’s 50 day simple moving average is $11.30 and its 200-day simple moving average is $8.57. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -18.35 and a beta of 3.29. Curis has a 1 year low of $0.76 and a 1 year high of $17.40.
Hedge funds have recently made changes to their positions in the stock. Pacer Advisors Inc. acquired a new position in shares of Curis in the first quarter valued at approximately $49,000. Total Clarity Wealth Management Inc. acquired a new position in shares of Curis in the first quarter valued at approximately $50,000. Captrust Financial Advisors acquired a new position in shares of Curis in the fourth quarter valued at approximately $41,000. Lindbrook Capital LLC acquired a new position in Curis during the 4th quarter worth approximately $57,000. Finally, Blair William & Co. IL acquired a new position in Curis during the 4th quarter worth approximately $82,000. Hedge funds and other institutional investors own 34.66% of the company’s stock.
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors.
See Also: What is a balanced fund?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.